Literature DB >> 17596302

De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Jianjiang Ye1, Lyndle Gradoville, Derek Daigle, George Miller.   

Abstract

The oncogenic human gammaherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), are latent in cultured lymphoma cells. We asked whether reactivation from latency of either virus requires de novo protein synthesis. Using Northern blotting and quantitative reverse transcriptase PCR, we measured the kinetics of expression of the lytic cycle activator genes and determined whether abundance of mRNAs encoding these genes from either virus was reduced by treatment with cycloheximide (CHX), an inhibitor of protein synthesis. CHX blocked expression of mRNAs of EBV BZLF1 and BRLF1, the two EBV lytic cycle activator genes, when HH514-16 Burkitt lymphoma cells were treated with histone deacetylase (HDAC) inhibitors, sodium butyrate or trichostatin A, or a DNA methyltransferase inhibitor, 5-Aza-2'-deoxycytidine. CHX also inhibited EBV lytic cycle activation in B95-8 marmoset lymphoblastoid cells by phorbol ester phorbol-12-myristate-13-acetate (TPA). EBV lytic cycle induction became resistant to CHX between 4 and 6 h after application of the inducing stimulus. KSHV lytic cycle activation, as assessed by ORF50 mRNA expression, was rapidly induced by the HDAC inhibitors, sodium butyrate and trichostatin A, in HH-B2 primary effusion lymphoma cells. In HH-B2 cells, CHX did not inhibit, but enhanced, expression of the KSHV lytic cycle activator gene, ORF50. In BC-1, a primary effusion lymphoma cell line that is dually infected with EBV and KSHV, CHX blocked EBV BRLF1 lytic gene expression induced by TPA and sodium butyrate; KSHV ORF50 mRNA induced simultaneously in the same cells by the same inducing stimuli was resistant to CHX. The experiments show, for the cell lines and inducing agents studied, that the EBV BZLF1 and BRLF1 genes do not behave with "immediate-early" kinetics upon reactivation from latency. KSHV ORF50 is a true "immediate-early" gene. Our results indicate that the mechanism by which HDAC inhibitors and TPA induce lytic cycle gene expression of the two viruses differs and suggest that EBV but not KSHV requires one or more proteins to be newly synthesized between 4 and 6 h after application of an inducing stimulus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596302      PMCID: PMC1951462          DOI: 10.1128/JVI.00982-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency.

Authors:  J Countryman; H Jenson; R Seibl; H Wolf; G Miller
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras.

Authors:  J L Kolman; N Taylor; L Gradoville; J Countryman; G Miller
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.

Authors:  F Le Roux; A Sergeant; L Corbo
Journal:  J Gen Virol       Date:  1996-03       Impact factor: 3.891

4.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

5.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Expression and regulation of retinoid X receptors in B16 melanoma cells.

Authors:  D S Desai; R M Niles
Journal:  J Cell Physiol       Date:  1995-11       Impact factor: 6.384

7.  Spontaneous and cycloheximide-induced interleukin-10 mRNA expression in human mononuclear cells.

Authors:  P Stordeur; L Schandené; P Durez; C Gérard; M Goldman; T Velu
Journal:  Mol Immunol       Date:  1995-03       Impact factor: 4.407

8.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.

Authors:  S Zalani; E Holley-Guthrie; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  26 in total

1.  Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.

Authors:  Jill K Countryman; Lyndle Gradoville; George Miller
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

2.  Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.

Authors:  Jill Countryman; Lyndle Gradoville; Sumita Bhaduri-McIntosh; Jianjiang Ye; Lee Heston; Sarah Himmelfarb; Duane Shedd; George Miller
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

3.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.

Authors:  Ya-Chun Yang; Yushi Yoshikai; Shih-Wei Hsu; Hisato Saitoh; Li-Kwan Chang
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

5.  Tousled-like kinases modulate reactivation of gammaherpesviruses from latency.

Authors:  Patrick J Dillon; Sean M Gregory; Kristen Tamburro; Marcia K Sanders; Gary L Johnson; Nancy Raab-Traub; Dirk P Dittmer; Blossom Damania
Journal:  Cell Host Microbe       Date:  2013-02-13       Impact factor: 21.023

Review 6.  Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.

Authors:  Denis Avey; Brittany Brewers; Fanxiu Zhu
Journal:  Virol Sin       Date:  2015-04-23       Impact factor: 4.327

7.  Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.

Authors:  Jianjiang Ye; Lyndle Gradoville; George Miller
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

8.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Authors:  David Ritchie; Richard L Piekarz; Piers Blombery; Laszlo J Karai; Stefania Pittaluga; Elaine S Jaffe; Mark Raffeld; John E Janik; H Miles Prince; Susan E Bates
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Proteomic analysis reveals selective impediment of neuronal remodeling upon Borna disease virus infection.

Authors:  Elsa Suberbielle; Alexandre Stella; Frédéric Pont; Céline Monnet; Emmanuelle Mouton; Lucile Lamouroux; Bernard Monsarrat; Daniel Gonzalez-Dunia
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.